Products & services directory

FDA-approved December 2022. PUNCH CD3 trial: 70.6% sustained clinical response at 8 weeks vs 57.5% placebo. First FDA-approved fecal microbiota product.

FDA-approved April 2023. ECOSPOR III trial: 87.6% sustained response at 8 weeks vs 60.4% placebo (p<0.001). First orally administered FDA-approved microbiome therapeutic.

Multiple meta-analyses support efficacy for AAD prevention (NNT ~10). AGA conditionally recommends for C. diff prevention in adults on antibiotics. Strain-specific evidence from >50 RCTs.

Strain-specific evidence from >20 RCTs for pediatric AAD prevention. AGA-recommended in specific pediatric contexts. Also studied for acute gastroenteritis (modest benefit), atopic dermatitis prevention (mixed).

Multiple RCTs demonstrate improvement in IBS global symptoms vs placebo. Whorwell et al. (2006) showed dose-dependent benefit at 10⁸ CFU. One of the few probiotics with IBS-specific evidence at a defined dose.

The De Simone Formulation (previously sold as VSL#3) has RCT evidence for pouchitis maintenance and UC adjunct therapy. AGA conditional recommendation for pouchitis. Note: VSL#3 and Visbiome are now different products due to a legal dispute; Visbiome contains the original formulation.

Depommier et al. (2019, Nat Med) Phase I/II showed pasteurized A. muciniphila improved insulin sensitivity and reduced cholesterol in overweight/obese subjects. Pendulum's formulation is live (not pasteurized). Their own trial (2024) showed improvement in A1c in T2DM patients on metformin.

Individual strains have varying levels of evidence. The specific combination has been tested in company-funded studies for gut barrier function, stool consistency, and skin outcomes. Published in peer-reviewed journals but needs independent replication.

Soluble fiber supplementation is well-established for increasing SCFA production and supporting commensal bacteria. Not strain-specific — feeds a broad range of bacteria. The simplest, best-supported intervention for most people.

Multiple RCTs show increased Bifidobacterium within 1 week of supplementation. Silk et al. (2009) showed improvement in IBS symptoms. One of the better-studied specific prebiotics. Also studied for reducing traveler's diarrhea incidence.

Based on PREDICT study data (Berry 2020, Nat Med). The science behind individual metabolic variation is real. ZOE's app translates this into food scores. Company-funded validation studies published in peer-reviewed journals.

Uses metatranscriptomics (gene expression), which is theoretically more informative than 16S or shotgun DNA. However, no published RCTs demonstrate health outcomes from following Viome recommendations. The personalized supplement formulations have not been clinically validated.

Uses validated sequencing methods. Provides compositional data, diversity scores, and functional predictions. Recommendations are algorithm-generated, not guideline-based.

FDA-cleared (De Novo pathway) as a prescription digital therapeutic for IBS. Randomized controlled trial showed significant improvement in IBS-SSS scores vs control. CBT for IBS is guideline-supported (AGA, ACG).

Not a microbiome product — but dietary fiber is the single best-supported intervention for gut microbiome health. Tracking fiber intake helps patients reach the 25–38g/day target. Cronometer specifically tracks fiber subtypes.

Traditional kefir contains a more diverse microbial community than commercial yogurt. Some RCTs show improved lactose digestion and modest GI symptom improvement. Part of the fermented foods category that increased diversity in the Stanford study (Wastyk 2021).

Included in the Stanford fermented food study that showed increased gut microbial diversity and decreased inflammatory markers (Wastyk 2021). Must be raw/unpasteurized to contain live cultures — shelf-stable sauerkraut is heat-treated and has no live organisms.

Contains some prebiotic fiber and probiotic cultures, but the strains are not clinically characterized for specific health outcomes. No published RCTs on the AG1 formula for any health outcome. Individual ingredient evidence doesn't validate the combination.

High CFU count and strain diversity sound impressive but have no established dose-response advantage. Individual strains are identified but the specific combination has never been tested in RCTs. 'More strains = better' is a marketing proposition, not a scientific finding.